TrialJournal of clinical pharmacology2018

Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.

Stephen Wring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.